ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Nadia Harbeck(Breast Center), Giuseppe Curigliano(European Institute of Oncology), Sherene Loi(The University of Melbourne), Christian F. Singer(Comprehensive Cancer Center Vienna), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Deborah Fenlon(Swansea University), David Krug(University Hospital Schleswig-Holstein), Javier Cortés(Villa Maria Hospital), Rebecca Dent(Duke-NUS Medical School), Jens Ricke(LMU Klinikum), Nicholas C. Turner(Institute of Cancer Research), Peter Schmid(St Bartholomew's Hospital), Frédérique Penault‐Llorca(Inserm), A. DeMichele(Hospital of the University of Pennsylvania), Sara A. Hurvitz(University of Washington), Wolfgang G. Kunz(LMU Klinikum), Seock‐Ah Im(Seoul National University), Sara M. Tolaney(Harvard University), Joseph Gligorov(Sorbonne Université), Evandro de Azambuja(Université Libre de Bruxelles), Cristina Saura(Vall d'Hebron Hospital Universitari), Sibylle Loibl(Goethe University Frankfurt), Hope S. Rugo(City of Hope), Carlos H. Barrios(Eastern Cooperative Oncology Group), Shani Paluch–Shimon(Hebrew University of Jerusalem), Tanja Španić(Unknown), Fabrice André(Inserm)
Cited by 1,358
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k